|
|
@@ -5,7 +5,7 @@ The study contains two data sets (raw):
|
|
|
- Arbaclofen (folder: arbaclofen) contains: 24-hour recordings at 8 weeks and 22 weeks, cross-over study VEP and AEP with 2 mg/kg arbaclofen at 8 weeks and 22 weeks.
|
|
|
|
|
|
#### File types
|
|
|
-The recording files are of the .edf+ type, meta data is provided as .yaml files and screenshots of the recording logs are available containing the exact transmitter frequency of each recording. The 24-hour recordings contain data from motion sensors recorded with Spike2 (CED) as .smrx format.
|
|
|
+The recordings were made in TainiLive. The recording files are of the .edf+ type, meta data is provided as .yaml files and screenshots of the recording logs are available containing the exact transmitter frequency of each recording. The 24-hour recordings contain data from motion sensors recorded with Spike2 (CED) as .smrx format.
|
|
|
|
|
|
## Characterization
|
|
|
|
|
|
@@ -52,7 +52,9 @@ e - poor signal at last recording
|
|
|
## Arbaclofen study
|
|
|
Longitudinal study of how acute administration of arbaclofen affect the Nrxn1α knock-out model. Arbaclofen (2 mg/kg) i saline was administered in a cross-over design at 8 weeks and 22 weeks of age.
|
|
|
|
|
|
-The data includes 24 hour recordings of spontaneous activity including video and a dose adjustment pilot with doses 3 mg/kg and 4 mg/kg.
|
|
|
+The data includes a dose adjustment pilot (folder: VEP/additional/dose-response) with doses 3 mg/kg and 4 mg/kg and VEP gating at 30 weeks (folder: VEP/additional/aging).
|
|
|
+
|
|
|
+#### Electrode configurations
|
|
|
|
|
|
Electrode configuration was the same as above for most of the animals, but for animals: 74979,74980,74981,74983,75023
|
|
|
The electrode configuration was as follows:
|
